APRelated
- Aurobindo Pharma tumbles 4%, hits 52-week low as USFDA issues 6 observations
- India may weigh negotiating preferential Trade Agreement with Oman: Piyush Goyal
- Oman to fast-track nods to Indian pharma products registered by US, UK, Europe
- Cipla skids 4% on Jan-Mar earnings miss
- PAG, partners buy controlling stake in Optimus for Rs 2,000 crore
Sun Pharmaceutical Industries on Thursday said it has received final approval from the US health regulator for Mesalamine extended release capsules, used to treat bowel disease, in the American market.
The company has received approval from the US Food and Drug Administration (USFDA) for the product, a generic version of Pentasa extended release capsules (500 mg), the Mumbai-based drug major said in a statement.
As per March 2022 IQVIA Health data, Pentasa had annualised sales of around USD 213 million in the US market.
The company has received approval from the US Food and Drug Administration (USFDA) for the product, a generic version of Pentasa extended release capsules (500 mg), the Mumbai-based drug major said in a statement.
As per March 2022 IQVIA Health data, Pentasa had annualised sales of around USD 213 million in the US market.
(Catch all the Business News, Breaking News Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
Read More News on
(Catch all the Business News, Breaking News Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
